Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

AstraZeneca PLC ADR (AZN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow AstraZeneca ADR's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create a new watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
55.56 -1.04    -1.84%
17/09 - Closed. Currency in USD ( Disclaimer )
After Hours
55.54
-0.02
-0.04%
0:41:35 - Real-time Data
  • Volume: 6,990,908
  • Bid/Ask: 55.31 / 55.54
  • Day's Range: 55.13 - 56.35
Type:  Equity
Market:  United States
ISIN:  US0463531089 
CUSIP:  046353108
AstraZeneca ADR 55.56 -1.04 -1.84%

AstraZeneca PLC ADR Company Profile

 
Read the Astrazeneca company profile to learn more about the business and the management team. View employee data, company address and contact information.
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

76100

Equity Type

ADR

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Contact Information

Address Cambridge, CB2 0AA
United Kingdom
Phone +44-20-73045000
Fax 20-76048151
Web www.astrazeneca.com/Home

Top Executives

Name Age Since Title
Andreas Rummelt 65 2021 Non-Executive Director
Euan A. Ashley 49 2020 Independent Non-Executive Director
Diana Layfield 50 2020 Independent Non-Executive Director
Marcus Wallenberg 65 1999 Non-Executive Director
Leif Johansson 70 2012 Independent Non-Executive Chairman
Pascal Soriot 62 2012 CEO & Executive Director
Nazneen Rahman 53 2017 Independent Non-Executive Director
Deborah DiSanzo Eldracher 61 2017 Independent Non-Executive Director
Shu Kam Mok 60 2019 Independent Non-Executive Director
Sherilyn S. D. McCoy 62 2017 Independent Non-Executive Director
Philip Arthur John Broadley 60 2017 Senior Independent Non-Executive Director
Michel Demare 65 2019 Independent Non-Executive Director
Aradhana Sarin 46 2021 CFO & Executive Director
Jeffrey Pott - 2009 EVP of HR, Chief HR Officer, General Counsel & Member of External Sustainability Advisory Board
Katarina Ageborg - 2011 EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
Menelas Pangalos - 2013 EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
Pam P. Cheng 50 2015 EVP of Operations & Information Technology and Member of External Sustainability Advisory Board
Polly Courtice 69 - Member of External Sustainability Advisory Board
Rain Henderson - - Member of External Sustainability Advisory Board
Pankaj Bhatia - - Member of External Sustainability Advisory Board
Louise Nicholls - - Member of External Sustainability Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

AZN Comments

Write your thoughts about AstraZeneca PLC ADR
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai May 09, 2021 11:35
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thanks you AstraZ. Bullish. management services.
Reply
1 0
Report
Woon soo Lee
Woon soo Lee May 01, 2021 18:12
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
54 to 64 bullish sentiments again volatility trading
Reply
1 0
Report
Poh Meng Kong
Poh Meng Kong Feb 25, 2021 22:08
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
$68 in 1 month
Reply
4 4
Report
Nelson T Machin
Nelson T Machin Feb 01, 2021 15:49
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Do you this will grow as EU has approved their Covid vaccine?
Reply
2 0
Report
Frans Caruana
Frans Caruana Jan 25, 2021 20:45
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
will reach 100 in 6 months time
Reply
4 0
Report
Arek Rusak
Arek Rusak Dec 24, 2020 13:15
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I think the vaccine is nothing next to the antibody coctail, known as AZD7442 that Astra is working on at the momenthttps://www.reuters.com/article/health-coronavirus-astrazeneca-antibody-idUSKBN28100E
Reply
0 0
Report
bojidar zarev
bojidar zarev Dec 14, 2020 18:56
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Good buy in the long term.
Reply
0 1
Report
Andre Low
Andre Low Dec 12, 2020 13:18
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://www.wsj.com/articles/astrazeneca-agrees-to-buy-alexion-for-39-billion-11607778687?redirect=amp#click=https://t.co/EeYlRyEn3g
Reply
0 0
Report
Nabeel Qabane
Nabeel Qabane Nov 30, 2020 10:27
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I expect it to reach $ 100 next month
Reply
0 1
Report
Sandeep Agarwal
Sandeep Agarwal Oct 12, 2020 17:24
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
for super rich returns
Reply
1 0
Report
Sandeep Agarwal
Sandeep Agarwal Oct 12, 2020 17:23
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
u need to hold it for a long term
Reply
1 0
Report
Alexandros Sfyroeras
Alexandros Sfyroeras Sep 09, 2020 8:40
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Attention , one of the trial subjects had serious implications , follow the news.
Reply
1 1
Report
Frans Caruana
Frans Caruana Aug 19, 2020 15:07
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
AstraZeneca will be the best vaccine
Reply
1 0
Report
Peter Lewis
Petelewis1994942 Jul 30, 2020 17:42
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
AZN are months ahead of their rivals - we’ll have a vaccine by October.
Reply
4 1
Report
aji koo
aji koo Jul 28, 2020 14:58
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Sinovac already had vaccine long before Moderna. But Moderna and Astrazenica have better global distribution...
Reply
0 0
Report
Wei Foong Wong
Wei Foong Wong Jul 20, 2020 17:22
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Interesting
Reply
0 0
Report
Frans Caruana
Frans Caruana Jul 17, 2020 15:04
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
first Moderna second AstraZeneca to provide vaccine in short time
Reply
1 2
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email